212 related articles for article (PubMed ID: 38761302)
21. Cost Offsets in the Treatment Journeys of Patients With Relapsed/Refractory Multiple Myeloma.
Ailawadhi S; DerSarkissian M; Duh MS; Lafeuille MH; Posner G; Ralston S; Zagadailov E; Ba-Mancini A; Rifkin R
Clin Ther; 2019 Mar; 41(3):477-493.e7. PubMed ID: 30773308
[TBL] [Abstract][Full Text] [Related]
22. Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia.
Tabchi S; Nair R; Kunacheewa C; Patel KK; Lee HC; Thomas SK; Amini B; Ahmed S; Mehta RS; Bashir Q; Qazilbash MH; Weber DM; Orlowski RZ; Alexanian R; Feng L; Manasanch EE
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):560-569. PubMed ID: 31201134
[TBL] [Abstract][Full Text] [Related]
23. Ixazomib-based frontline therapy followed by ixazomib maintenance in frail elderly newly diagnosed with multiple myeloma: a prospective multicenter study.
Bao L; Wang YT; Liu P; Lu MQ; Zhuang JL; Zhang M; Xia ZJ; Li ZL; Yang Y; Yan ZY; Jing HM; Dong F; Chen WM; Wu Y; Zhou HB; Fu R; Gong YP; Huang WR; Zhang YQ
EClinicalMedicine; 2024 Feb; 68():102431. PubMed ID: 38318126
[TBL] [Abstract][Full Text] [Related]
24. Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study).
Lee HS; Kim K; Kim SJ; Lee JJ; Kim I; Kim JS; Eom HS; Yoon DH; Suh C; Shin HJ; Mun YC; Kim MK; Lim SN; Choi CW; Kang HJ; Yoon SS; Min CK;
Am J Hematol; 2020 Apr; 95(4):413-421. PubMed ID: 31919872
[TBL] [Abstract][Full Text] [Related]
25. New regimens and directions in the management of newly diagnosed multiple myeloma.
Bal S; Giri S; Godby KN; Costa LJ
Am J Hematol; 2021 Mar; 96(3):367-378. PubMed ID: 33393136
[TBL] [Abstract][Full Text] [Related]
26. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
27. A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan.
Horigome Y; Iino M; Harazaki Y; Kobayashi T; Handa H; Hiramatsu Y; Kuroi T; Tanimoto K; Matsue K; Abe M; Ishida T; Ito S; Iwasaki H; Kuroda J; Shibayama H; Sunami K; Takamatsu H; Tamura H; Hayashi T; Akagi K; Maeda T; Yoshida T; Mori I; Shinozaki T; Iida S
Ann Hematol; 2024 Feb; 103(2):475-488. PubMed ID: 37695378
[TBL] [Abstract][Full Text] [Related]
28. Phase II clinical trial of personalized VCD-VTD sequential therapy using the Vulnerable Elders Survey-13 (VES-13) for transplant-ineligible patients with newly diagnosed multiple myeloma.
Nakazato T; Hagihara M; Sahara N; Tamai Y; Ishii R; Tamaki S; Wake A; Tajika K; Sakai R; Kobayashi T; Hua J; Inoue M; Aisa Y; Fujisawa S; Miyazaki K; Irie S; Tanaka E; Higashihara M
Ann Hematol; 2021 Nov; 100(11):2745-2754. PubMed ID: 34333665
[TBL] [Abstract][Full Text] [Related]
29. Impact of Frailty on Outcomes after Chimeric Antigen Receptor T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma.
Davis JA; Dima D; Ahmed N; DeJarnette S; McGuirk J; Jia X; Raza S; Khouri J; Valent J; Anwer F; Abdallah AO; Hashmi H
Transplant Cell Ther; 2024 Mar; 30(3):298-305. PubMed ID: 38142943
[TBL] [Abstract][Full Text] [Related]
30. Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd.
Chari A; Richardson PG; Romanus D; Dimopoulos MA; Sonneveld P; Terpos E; Hajek R; Raju A; Palumbo A; Cain LE; Blazer M; Huang H; Farrelly E; Ailawadhi S
Expert Rev Hematol; 2020 Apr; 13(4):421-433. PubMed ID: 32148109
[TBL] [Abstract][Full Text] [Related]
31. Recent advances in the management of older adults with newly diagnosed multiple myeloma in Japan.
Suzuki T; Maruyama D; Iida S; Nagai H
Jpn J Clin Oncol; 2022 Sep; 52(9):966-974. PubMed ID: 35830865
[TBL] [Abstract][Full Text] [Related]
32. Comparison of Frailty Scores in Newly Diagnosed Patients with Multiple Myeloma: A Review.
Mian H; Brouwers M; Kouroukis CT; Wildes TM
J Frailty Aging; 2019; 8(4):215-221. PubMed ID: 31637409
[TBL] [Abstract][Full Text] [Related]
33. A prospective observational study to assess clinical decision-making, prognosis, quality of life and satisfaction with care in patients with relapsed/refractory multiple myeloma: the CLARITY study protocol.
Efficace F; Boccadoro M; Palumbo A; Petrucci MT; Cottone F; Cannella L; Zamagni E; Niscola P; Kyriakou C; Caravita T; Offidani M; Mandelli F; Cavo M
Health Qual Life Outcomes; 2018 Jun; 16(1):127. PubMed ID: 29914509
[TBL] [Abstract][Full Text] [Related]
34. Electronic FRAIL score may predict treatment outcomes in older adults with myeloma.
Chan H; Chong YH; Seow MY; Li J; Garg P; Kelly M; Neylon A; McDiarmid B; Tan S; Jackson S
J Geriatr Oncol; 2021 May; 12(4):515-520. PubMed ID: 33046409
[TBL] [Abstract][Full Text] [Related]
35. Measuring Frailty Using Patient-Reported Outcomes (PRO) Data: A Feasibility Study in Patients with Multiple Myeloma.
Murugappan MN; King-Kallimanis BL; Bhatnagar V; Kanapuru B; Farley JF; Seifert RD; Stenehjem DD; Chen TY; Horodniceanu EG; Kluetz PG
Qual Life Res; 2023 Aug; 32(8):2281-2292. PubMed ID: 36935467
[TBL] [Abstract][Full Text] [Related]
36. A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis.
Dimopoulos MA; Kaufman JL; White D; Cook G; Rizzo M; Xu Y; Fahrbach K; Gaudig M; Slavcev M; Dearden L; Lam A
Clin Lymphoma Myeloma Leuk; 2018 Mar; 18(3):163-173.e6. PubMed ID: 29456035
[TBL] [Abstract][Full Text] [Related]
37. Daratumumab Treatment for "Truly Frail" Elderly Myeloma Patients.
Horigome Y; Suzuki K; Suzuki T
Life (Basel); 2024 Mar; 14(3):. PubMed ID: 38541713
[TBL] [Abstract][Full Text] [Related]
38. Development of a new clinical index to easily assess frailty of elderly patients with multiple myeloma in Asian population.
Lee HS; Lee J; Jo JC; Jung SH; Lee JJ; Kim D; Lee S; Song K
Sci Rep; 2021 Nov; 11(1):22907. PubMed ID: 34824362
[TBL] [Abstract][Full Text] [Related]
39. Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
Cohen YC; Magen H; Lavi N; Gatt ME; Chubar E; Horowitz N; Kreiniz N; Tadmor T; Trestman S; Vitkon R; Rouvio O; Shvetz O; Shaulov A; Ziv-Baran T; Avivi I
Ann Hematol; 2020 Jun; 99(6):1273-1281. PubMed ID: 32193630
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and Toxicity Profile of Carfilzomib-Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review.
Imtiaz H; Khan M; Ehsan H; Wahab A; Rafae A; Khan AY; Jamil A; Sana MK; Jamal A; Ali TJ; Ansar I; Khan MM; Khouri J; Anwer F
Onco Targets Ther; 2021; 14():4941-4960. PubMed ID: 34629878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
